期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 88, 期 1, 页码 29-39出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2022.07.002
关键词
apremilast; clinical trial; deucravacitinib; efficacy; phase 3; psoriasis; Psoriasis Area and Severity Index; safety; skin diseases; static Physician's Global Assessment
类别
This study compared the efficacy and safety of deucravacitinib with placebo and apremilast in adults with moderate to severe plaque psoriasis. The results showed that deucravacitinib was more effective than placebo and apremilast in reducing symptoms and improving skin lesions, and the adverse event rates were similar among the three drugs.
Background: Effective, well-tolerated oral psoriasis treatments are needed. Objective: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis. Methods: Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary end points included response rates for $75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at week 16. Results: At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P\.0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P\.0001). Efficacy improved beyond week 16 and was maintained through week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast. Limitations: One-year duration, limited racial diversity. Conclusion: Deucravacitinib was superior to placebo and apremilast across multiple efficacy end points and was well tolerated in moderate to severe plaque psoriasis. ( J Am Acad Dermatol 2023;88:29-39.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据